Stockscreener 앱 받기
2.04
0.49%
0.01
시간 외 거래:
2.04
전일 마감가:
$2.03
열려 있는:
$2.0856
하루 거래량:
25,983
Relative Volume:
1.30
시가총액:
$13.34M
수익:
-
순이익/손실:
$-7.72M
주가수익비율:
-0.7729
EPS:
-2.6394
순현금흐름:
$-6.25M
1주 성능:
+1.75%
1개월 성능:
+2.51%
6개월 성능:
+7.05%
1년 성능:
-51.54%
1일 변동 폭
$2.035
$2.11
1주일 범위
$1.91
$2.14
52주 변동 폭
$1.55
$5.59
에데사 바이오테크 Stock (EDSA) Company Profile
명칭
Edesa Biotech Inc
전화
(905) 475-1234
주소
100 SPY COURT, MARKHAM, ON
EDSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
2.04 | 13.34M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
에데사 바이오테크 주식(EDSA)의 최신 뉴스
Edesa Biotech secures up to C$23 million in funding under the Federal Government’s Strategic Innovation Fund for pivotal clinical study - Fasken
Edesa Biotech, Inc. closes US$10 million bought deal offering of common shares - Fasken
40,944 Shares in Edesa Biotech, Inc. (NASDAQ:EDSA) Bought by Citadel Advisors LLC - Defense World
Edesa Biotech Shareholders Approve Key Proposals at AGM - TipRanks
Edesa Biotech (EDSA) Receives Buy Rating from Lucid Capital | ED - GuruFocus
Zacks Small Cap Reduces Earnings Estimates for Edesa Biotech - Defense World
EDSA: Advancing EB06 for the Treatment of Vitiligo - Research Tree
EDSA: Advancing EB06 for the Treatment of Vitiligo… - Yahoo Finance
Positive Signs As Multiple Insiders Buy Edesa Biotech Stock - Yahoo Finance
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results - GlobeNewswire
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025 - TipRanks
Edesa Biotech Q2 EPS USD -0.3 - marketscreener.com
Edesa Biotech Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Edesa Biotech Reports Q2 2025 Financial Results and Advances Vitiligo Drug Development Efforts - Nasdaq
Edesa Biotech Advances Novel Vitiligo Treatment with $15M Backing from Healthcare Investors - Stock Titan
Edesa Biotech Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
Edesa Biotech (EDSA) to Release Quarterly Earnings on Friday - Defense World
Edesa Biotech to Present at 2024 Bloom Burton Healthcare Investor Conference - TipRanks
Edesa Biotech to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference in Toronto - Nasdaq
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference - GlobeNewswire
Edesa Biotech Showcases Immuno-Inflammatory Pipeline at Bloom Burton Healthcare Conference - Stock Titan
Edesa Biotech (NASDAQ:EDSA) Shares Up 3% – Time to Buy? - Defense World
Healthcare Veteran Returns to NeuPath as President, Armed with Ambitious Expansion Plan - Stock Titan
Edesa Biotech secures $15 million for clinical program - MSN
Edesa Biotech (NASDAQ:EDSA) and Earth Science Tech (OTCMKTS:ETST) Head-To-Head Review - Defense World
Edesa Biotech says Peter Weiler to succeed Stephen Lemieux as CFO - MSN
Nuvectis Pharma (NASDAQ:NVCT) and Edesa Biotech (NASDAQ:EDSA) Critical Analysis - Defense World
Edesa Biotech Announces Chief Financial Officer Transition - GlobeNewswire
Edesa Biotech announces CFO transition - MSN
Edesa Biotech names Peter Weiler as new CFO By Investing.com - Investing.com South Africa
Edesa Biotech (EDSA) Shares Drop After New CFO Announcement - GuruFocus
Edesa Biotech Appoints New CFO Amid Leadership Change - TipRanks
Edesa Biotech names Peter Weiler as new CFO - Investing.com
Edesa Biotech Hires Peter Weiler From Exzell Pharma to be New CFO - marketscreener.com
Edesa Biotech, Inc. Announces Chief Financial Officer Changes, Effective May 1, 2025 - MarketScreener
HC Wainwright Comments on Edesa Biotech Q2 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Edesa Biotech (NASDAQ:EDSA) - Defense World
H.C. Wainwright maintains $21 target on Edesa Biotech shares By Investing.com - Investing.com Australia
H.C. Wainwright maintains $21 target on Edesa Biotech shares - Investing.com India
Hidden Gems: 5 Stocks Under $10 With Massive Growth Potential - The Globe and Mail
Edesa Biotech completes US$15 million private placement - Fasken
You Won't Believe What Nvidia CEO Jensen Huang Just Said - The Globe and Mail
Edesa Biotech files to sell 7.81M common shares for holders - MSN
Nvidia Stock Isn’t So Magnificent Anymore. Is It Time to Sell Shares Now? - The Globe and Mail
Zacks Small Cap Boosts Earnings Estimates for Edesa Biotech - Defense World
EDSA: Raises 15 Million to Advance EB06 - Smartkarma
EDSA: Raises $15 Million to Advance EB06… - Yahoo Finance
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
Biotech Stocks To Keep An Eye On – February 13th - Defense World
에데사 바이오테크 (EDSA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):